Intravesical High Dose BCG Tokyo and Low Dose BCG Tokyo with <i>GMCSF+IFN α </i> Induce Systemic Immunity in a Murine Orthotopic Bladder Cancer Model
This study evaluates a short therapy schedule for bladder cancer using BCG Tokyo. BCG Tokyo was evaluated in vitro using bone marrow derived dendritic cells, neutrophils, RAW macrophages and the murine bladder cancer cell line, MB49PSA, and compared to other BCG strains. BCG Tokyo > BCG TICE at i...
Main Authors: | Sin Mun Tham, Juwita N. Rahmat, Edmund Chiong, Qinghui Wu, Kesavan Esuvaranathan, Ratha Mahendran |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-11-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9059/9/12/1766 |
Similar Items
-
BCG and Kawasaki disease in Mexico and Japan
by: Luisa Berenise Gamez-Gonzalez, et al.
Published: (2017-05-01) -
Pott's disease post intravesical BCG
by: Anika Jain
Published: (2023-01-01) -
Genome sequences of BCG Pasteur ATCC 35734 and its derivative, the vaccine candidate BCGΔBCG1419c
by: Giuseppe D’Auria, et al.
Published: (2023-02-01) -
BCG Sepsis After Intravesical BCG Instillation: A Case Report
by: Meliha Çağla Sönmezer, et al.
Published: (2019-03-01) -
Compared Efficacy of Adjuvant Intravesical BCG-TICE vs. BCG-RIVM for High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC): A Propensity Score Matched Analysis
by: Francesco Del Giudice, et al.
Published: (2022-02-01)